SCHEMBL5200741

SCHEMBL5200741

CCC(OC(C)=O)C(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
LMNA P02545 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GALR3 O60755 1/20 0.34
MAPT P10636 1/20 0.34
BLM P54132 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
ALOX15 P16050 1/20 0.32
MEN1 O00255 1/20 0.31
CYP1A2 P05177 1/20 0.31
HRH1 P35367 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11131878 0.82 TSHR (0.37) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL27480081 0.82 TSHR (0.37) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL23779935 0.82 TSHR (0.37) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL23779934 0.82 TSHR (0.37) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL12314325 0.80 TSHR (0.43) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL12314349 0.80 TSHR (0.43) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL28558437 0.79 LMNA (0.38) TSHRCHRM2CHRM4CHRM1LMNA
SCHEMBL13326291 0.79 TSHR (0.39) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL10892018 0.79 TSHR (0.39) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL28565430 0.79 LMNA (0.38) TSHRCHRM2CHRM4CHRM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016108206-A2 PROCESSES FOR PREPARATION OF IDELALISIB AND INTERMEDIATES THEREOF DR. REDDY’S LABORATORIES LIMITED (IN) 2016-07-07 WO disclosed
WO-2016108206-A2 PROCESSES FOR PREPARATION OF IDELALISIB AND INTERMEDIATES THEREOF DR. REDDY’S LABORATORIES LIMITED (IN) 2016-07-07 WO disclosed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 TSHR 556/4885CHRM2 1845/4885CHRM4 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.